Benzinga's Top Pre-Market NASDAQ Losers (OREX, VVUS, CCME, DEPO)

Orexigen Therapeutics Inc OREX dipped 73.82% to $2.38 in the pre-market session. The Food and Drug Administration (FDA) declined to approve the OREX's diet drug Contrave. VIVUS Inc VVUS fell 7.82% to $8.25 in the pre-market session. VVUS' PEG ratio is -0.17. China MediaExpress Holdings Inc CCME moved down 4.71% to $17 in the pre-market session. CCME's trailing-twelve-month revenue is $186.94 million. Depomed Inc DEPO dropped 2.51% to $8.17 in the pre-market trading. US regulators approved DEPO's drug Gralise. Read more from Benzinga's Markets.